Redcare appoints Peter Schmid CEO: Redcare Pharmacy stock sits 5.17 percent below high
Published on 10/23/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership change and growth outlook
- Peter Schmid von Linstow became CEO on October 14, 2026.
- Full-year 2026 revenue growth guidance rose to 16 to 18 percent on September 28, 2026.
- Redcare Pharmacy stock trades at EUR 78.28 at 10:04 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.22 percent below the Xetra close of October 22, 2026.
- Second-quarter 2026 revenue reached EUR 853.5 million and net profit EUR 4.7 million.
Redcare Pharmacy (ISIN NL0012044747) trades at EUR 78.28 at Lang & Schwarz on October 23, 2026 at 10:04 a.m. CEST, 0.22 percent below the Xetra close of October 22, 2026 at EUR 78.45. The company appointed Peter Schmid von Linstow as chief executive officer on October 14, 2026, placing leadership execution alongside the next quarterly update.
New CEO takes charge
According to Redcare Pharmacy, Schmid von Linstow joined the Managing Board and became CEO with immediate effect on October 14, 2026. The company said his background includes more than 20 years of leadership experience at digital platforms and marketplaces.
The change comes before the company reports third-quarter 2026 figures. That timing makes the October update the first scheduled test of the new CEO's financial and operational priorities.
Guidance points to Rx growth
Redcare raised full-year 2026 total revenue growth guidance to 16 to 18 percent from 15 to 17 percent on September 28, 2026. NewMediaWire reported that German prescription revenue was expected at EUR 730 million to EUR 760 million for full-year 2026, up from EUR 680 million to EUR 720 million previously. Adjusted EBITDA margin guidance remained 2.5 to 3.0 percent.
Three dates frame the story
On June 30, 2026, second-quarter revenue was EUR 853.5 million and net profit was EUR 4.7 million, according to Markets Insider. On September 28, 2026, management lifted the revenue growth range to 16 to 18 percent. On October 14, 2026, Schmid von Linstow became CEO.
What comes next for margins?
Redcare is scheduled to publish its interim statement for the third quarter of 2026 on October 29, 2026, followed by a quarterly conference call, according to NewMediaWire. The main operating question is whether prescription growth can support the guided 2.5 to 3.0 percent adjusted EBITDA margin while the leadership transition settles.
Stock stays below yearly high
At EUR 78.28, the stock was 5.17 percent below its 52-week high of EUR 82.55 on October 23, 2026. A recent analysis highlighted execution and logistics investment as factors that could influence the path from revenue growth to profit, while also pointing to risks from slower electronic prescription adoption.
Redcare Pharmacy was trading at EUR 78.28 at Lang & Schwarz on October 23, 2026 at 10:04 a.m. CEST, 0.22 percent below the Xetra close of October 22, 2026 at EUR 78.45. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy stock facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- WKN: A2AR94
- Ticker: RDC
- Primary exchange: Frankfurt Stock Exchange
- Price Lang & Schwarz (as of October 23, 2026, 10:04 a.m. CEST): EUR 78.28
- Change versus Xetra close: minus 0.22 percent
- Xetra close (October 22, 2026): EUR 78.45
- Market capitalization: EUR 1.6 billion (as of October 23, 2026)
- 52-week range: EUR 30.20-EUR 82.55 (as of October 23, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report SDAX.
